FADS2 and metabolic dysfunction-associated steatotic liver disease: This result is contrary to the previous report of increased expression of Fads2 and Scd1 in NASH patients (Chiappini et al., 2017) and could represent differences associated with chemical-induced steatosis vs general NAFLD.